ImmuneOnco Biopharmaceuticals (Shanghai) Balance Sheet Health
Financial Health criteria checks 5/6
ImmuneOnco Biopharmaceuticals (Shanghai) has a total shareholder equity of CN¥600.2M and total debt of CN¥86.0M, which brings its debt-to-equity ratio to 14.3%. Its total assets and total liabilities are CN¥743.3M and CN¥143.0M respectively.
Key information
14.3%
Debt to equity ratio
CN¥85.99m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥513.04m |
| Equity | CN¥600.24m |
| Total liabilities | CN¥143.03m |
| Total assets | CN¥743.27m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 1541's short term assets (CN¥582.6M) exceed its short term liabilities (CN¥119.8M).
Long Term Liabilities: 1541's short term assets (CN¥582.6M) exceed its long term liabilities (CN¥23.3M).
Debt to Equity History and Analysis
Debt Level: 1541 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if 1541's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 1541 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 1541 has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 20.7% each year.